Skip to content

Study · Non-randomized trial · 2022

6 results

Differences in sex hormone recovery profile after cessation of 12-week gonadotropin-releasing hormone antagonist versus agonist therapy.

Sasaki H, Miki K, Tashiro K, Mori K, Urabe F, Fukuokaya W, Kimura T, Sato S, Takahashi H, Aoki M, Egawa S

Andrology24 Sept 2021Cited by 6 (Europe PMC)

PMID34510814 (opens in a new tab)DOI10.1111/andr.13107 (opens in a new tab)PepBankPUB-34510814
Publisher pagePubMedAsk about this study
Jump to 6 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study6

6 results from studies that gave the peptide. 6 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, testosterone recovery after the last injection took longer with degarelix than GnRH agonists (median 27.3 versus 4.8 weeks, p < 0.001).

    In plain wordsIn localized prostate cancer, testosterone recovery took longer after degarelix than after GnRH agonists.

    Peptide
    Degarelix
    Outcome
    IncreaseTestosterone recovery duration
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Analysis
    Primary
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Measurements

    Testosterone recovery duration after last injection
    27.3 weeks
    Degarelix (GnRH antagonist) arm, median
    Testosterone recovery duration after last injection
    4.8 weeks
    GnRH agonist arm, median

    Source sentences

    Summary
    Testosterone recovery duration after the last injection was significantly longer in the GnRH antagonist arm than in the GnRH agonist arm (median, 27.3 vs. 4.8 weeks, p < 0.001).
    3 context sentences
    Summary · context
    The primary endpoint was a serum testosterone level above the castration range (>50 ng/dl) after the cessation of 12-week neoadjuvant ADT (GnRH antagonist or GnRH agonists).
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.
  2. 02HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, luteinizing hormone remained lower after degarelix than GnRH agonists between 16 and 24 weeks (p < 0.01).

    In plain wordsIn localized prostate cancer, luteinizing hormone remained lower after degarelix than after GnRH agonists.

    Peptide
    Degarelix
    Outcome
    DecreaseLuteinizing hormone
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The serum levels of luteinizing hormone and follicle-stimulating hormone in the GnRH antagonist arm also remained significantly lower than those in the GnRH agonist arm between 16 and 24 weeks (p < 0.01).
    2 context sentences
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.
  3. 03HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, follicle-stimulating hormone remained lower after degarelix than GnRH agonists between 16 and 24 weeks (p < 0.01).

    In plain wordsIn localized prostate cancer, follicle-stimulating hormone remained lower after degarelix than after GnRH agonists.

    Peptide
    Degarelix
    Outcome
    DecreaseFollicle-stimulating hormone
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    The serum levels of luteinizing hormone and follicle-stimulating hormone in the GnRH antagonist arm also remained significantly lower than those in the GnRH agonist arm between 16 and 24 weeks (p < 0.01).
    2 context sentences
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.
  4. 04HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, prostate volume reduction at brachytherapy was comparable after degarelix and GnRH agonists (p = 0.128).

    In plain wordsIn localized prostate cancer, prostate volume reduction was comparable after degarelix and GnRH agonists.

    Peptide
    Degarelix
    Outcome
    No significant changeTotal prostate volume reduction
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Outcome group
    Prostate volume · Reproductive and sexual health
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    Meanwhile, reduction in TPV at the time of TPPB was comparable between both arms (p = 0.128).
    2 context sentences
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.
  5. 05HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, International Prostate Symptom Scores did not differ significantly between degarelix and GnRH agonist arms.

    In plain wordsIn localized prostate cancer, urinary symptom scores did not differ significantly between degarelix and GnRH agonists.

    Peptide
    Degarelix
    Outcome
    No significant changeInternational Prostate Symptom Score
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were also no significant between-arm differences in the International Prostate Symptom Score and the International Index of Erectile Function scores.
    2 context sentences
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.
  6. 06HumanNon-randomized trialEfficacy outcome

    In localized prostate cancer, International Index of Erectile Function scores did not differ significantly between degarelix and GnRH agonist arms.

    In plain wordsIn localized prostate cancer, erectile function scores did not differ significantly between degarelix and GnRH agonists.

    Peptide
    Degarelix
    Outcome
    No significant changeInternational Index of Erectile Function
    Study

    n: not reported in source

    Comparator
    GnRH agonist (leuprorelin acetate or goserelin acetate)
    Outcome group
    Sexual function · Reproductive and sexual health
    Studied dose
    Dose not stated · 12 weeksAs given in this study (human).

    Source sentences

    Summary
    There were also no significant between-arm differences in the International Prostate Symptom Score and the International Index of Erectile Function scores.
    2 context sentences
    Summary · context
    We aimed to elucidate the difference in recovery profile between GnRH antagonist (degarelix) and GnRH agonist (leuprorelin acetate or goserelin acetate) as short-term (12 weeks) neoadjuvant androgen deprivation therapy (ADT) prior to 125I-transperineal prostate brachytherapy (TPPB) for localized prostate cancer.
    Summary · context
    This study was initially designed as a single-center, prospective, open-label, randomized controlled trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 4Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Versions 2 to 3

    27 Oct 2026, 16:37 UTC

    The same notice was added 2 times, first on 27 Oct 2026, 16:35 UTC. The status did not change between them.

    Study data updated · source update from Europe PMC

  3. Version 1

    27 Oct 2026, 16:34 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.